CTOs on the Move

MOLLI Surgical

www.mollisurgical.com

 
#Healthcare needs to get simpler to get better. To achieve this, we focus on the #patientexperience and develop more effective #medicaldevices. #breastcancer
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

St. Joseph Orphanage

St. Joseph Orphanage provides a variety of behavioral health services for children, teens, and adults across Southwest Ohio - Locations: Cincinnati & Dayton

NeurAbilities Healthcare

The premier provider of comprehensive and coordinated neurological and behavioral services in New Jersey and Pennsylvania, offering comfort, hope and answers that transform individuals and their families.

GuideStar Clinical

GuideStar works with hospitals, health systems and physician practices around the country to build, manage and support clinical research programs. From helping incorporate a clinical trial strategy to providing management guidance and support, our service delivery is based on operational and financial best practices to ensure optimal results for research programs.

TFF Pharmaceuticals

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.